Ascendis Pharma A (ASND) Operating Margin (2014 - 2026)
Ascendis Pharma A (ASND) posted Operating Margin of 10.06% for Q1 2026, up 323.42% sequentially from 2.38% in Q4 2025, and up 11329.0% YoY from N/an in Q1 2025.
Ascendis Pharma A (ASND) Operating Margin (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported Operating Margin for 13 years, with the latest figure at 10.06% in Q1 2026.
- Quarterly Operating Margin rose 11329.0% year-over-year to 10.06% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.54% (down 7576475.0% YoY) and the FY2025 annual result came in at 18.92%, up 4978.0% from the prior year.
- Operating Margin improved to 10.06% in Q1 2026 per ASND's latest filing, from 2.38% in the prior quarter.
- Over five years, Operating Margin peaked at 123555.16% in Q4 2024 and troughed at 2303.46% in Q2 2022.
- A 5-year average of 6827.24% and a median of 167.28% in 2024 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2024 and 2025: Operating Margin jumped 12356726 bps in 2024, then plunged 12355279 bps in 2025.
- Over 5 years, Operating Margin stood at 643.75% in 2022, then soared by 98 bps to 12.09% in 2023, then surged by 1021723 bps to 123555.16% in 2024, then sank by 100 bps to 2.38% in 2025, then surged by 323 bps to 10.06% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 10.06%, 2.38%, and 5.15% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 10.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.06% |
| Dec 31, 2025 | 2.38% |
| Sep 30, 2025 | 5.15% |
| Jun 30, 2025 | -33.50% |
| Mar 31, 2025 | -103.23% |
| Dec 31, 2024 | 123,555.16% |
| Sep 30, 2024 | -167.28% |
| Jun 30, 2024 | -370.18% |
| Mar 31, 2024 | -51.25% |
| Dec 31, 2023 | -12.09% |
| Sep 30, 2023 | -279.82% |
| Jun 30, 2023 | -297.17% |
| Mar 31, 2023 | -427.77% |
| Dec 31, 2022 | -643.75% |
| Sep 30, 2022 | -945.09% |
| Jun 30, 2022 | -2,303.46% |
| Mar 31, 2022 | -1,875.06% |
| Dec 31, 2021 | -130.71% |
| Sep 30, 2021 | -8,709.07% |
| Jun 30, 2021 | -11,509.69% |